-$0.08 Earnings Per Share Expected for Catalyst Pharmaceuticals Inc (CPRX) This Quarter

Share on StockTwits

Equities analysts expect that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will post earnings of ($0.08) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Catalyst Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.11). Catalyst Pharmaceuticals reported earnings per share of ($0.05) in the same quarter last year, which would suggest a negative year over year growth rate of 60%. The firm is scheduled to issue its next earnings report on Wednesday, November 14th.

According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full-year earnings of ($0.29) per share for the current fiscal year, with EPS estimates ranging from ($0.38) to ($0.24). For the next year, analysts anticipate that the company will report earnings of ($0.13) per share, with EPS estimates ranging from ($0.35) to ($0.02). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Friday, August 10th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.02.

CPRX has been the topic of a number of recent research reports. Cantor Fitzgerald initiated coverage on shares of Catalyst Pharmaceuticals in a report on Thursday, September 20th. They issued an “overweight” rating and a $8.00 price objective on the stock. BidaskClub upgraded shares of Catalyst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, September 27th. Oppenheimer set a $6.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 9th. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price objective on the stock in a report on Monday, August 13th. Finally, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, August 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $5.61.

CPRX traded down $0.04 during midday trading on Friday, reaching $3.31. The company’s stock had a trading volume of 965,500 shares, compared to its average volume of 689,179. The stock has a market cap of $357.05 million, a PE ratio of -15.76 and a beta of 1.46. Catalyst Pharmaceuticals has a 1 year low of $2.18 and a 1 year high of $4.51.

Several hedge funds and other institutional investors have recently modified their holdings of CPRX. Prudential Financial Inc. lifted its stake in shares of Catalyst Pharmaceuticals by 44.5% in the first quarter. Prudential Financial Inc. now owns 173,670 shares of the biopharmaceutical company’s stock worth $415,000 after buying an additional 53,500 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of Catalyst Pharmaceuticals by 24.3% in the first quarter. Schwab Charles Investment Management Inc. now owns 184,904 shares of the biopharmaceutical company’s stock worth $442,000 after buying an additional 36,200 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Catalyst Pharmaceuticals by 22.5% in the first quarter. Northern Trust Corp now owns 1,009,947 shares of the biopharmaceutical company’s stock worth $2,414,000 after buying an additional 185,639 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Catalyst Pharmaceuticals by 16.9% in the first quarter. BlackRock Inc. now owns 4,698,531 shares of the biopharmaceutical company’s stock worth $11,230,000 after buying an additional 678,950 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its stake in shares of Catalyst Pharmaceuticals by 47.6% in the first quarter. New York State Common Retirement Fund now owns 74,994 shares of the biopharmaceutical company’s stock worth $179,000 after buying an additional 24,200 shares in the last quarter. Hedge funds and other institutional investors own 51.49% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Further Reading: What are the components of an earnings report?

Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply